KR20040081165A - 펩타이드 항체 및 이를 이용한 아밀로이드-관련 질환의진단 및 치료 방법 - Google Patents
펩타이드 항체 및 이를 이용한 아밀로이드-관련 질환의진단 및 치료 방법 Download PDFInfo
- Publication number
- KR20040081165A KR20040081165A KR10-2004-7011868A KR20047011868A KR20040081165A KR 20040081165 A KR20040081165 A KR 20040081165A KR 20047011868 A KR20047011868 A KR 20047011868A KR 20040081165 A KR20040081165 A KR 20040081165A
- Authority
- KR
- South Korea
- Prior art keywords
- peptide
- amino acid
- group
- pharmaceutical composition
- seq
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1016—Tetrapeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/585—Calcitonins
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0819—Tripeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1002—Tetrapeptides with the first amino acid being neutral
- C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
- C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/10—Tetrapeptides
- C07K5/1021—Tetrapeptides with the first amino acid being acidic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Veterinary Medicine (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurosurgery (AREA)
- Gastroenterology & Hepatology (AREA)
- Diabetes (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Endocrinology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Psychiatry (AREA)
- Emergency Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (9)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35257802P | 2002-01-31 | 2002-01-31 | |
US60/352,578 | 2002-01-31 | ||
US39226602P | 2002-07-01 | 2002-07-01 | |
US60/392,266 | 2002-07-01 | ||
US10/235,852 US20040052928A1 (en) | 2002-09-06 | 2002-09-06 | Peptides and methods using same for diagnosing and treating amyloid-associated diseases |
US10/235,852 | 2002-09-06 | ||
US43645302P | 2002-12-27 | 2002-12-27 | |
US60/436,453 | 2002-12-27 | ||
PCT/IL2003/000079 WO2003063760A2 (en) | 2002-01-31 | 2003-01-30 | Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20040081165A true KR20040081165A (ko) | 2004-09-20 |
Family
ID=27671045
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR10-2004-7011868A KR20040081165A (ko) | 2002-01-31 | 2003-01-30 | 펩타이드 항체 및 이를 이용한 아밀로이드-관련 질환의진단 및 치료 방법 |
Country Status (6)
Country | Link |
---|---|
EP (1) | EP1534310A4 (de) |
JP (1) | JP2006506942A (de) |
KR (1) | KR20040081165A (de) |
AU (1) | AU2003207973A1 (de) |
CA (1) | CA2473987C (de) |
WO (1) | WO2003063760A2 (de) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180061982A (ko) * | 2016-11-30 | 2018-06-08 | 연세대학교 산학협력단 | 세포 내부 pH 감응성 융합 펩티드 및 이를 유효성분으로 포함하는 단백질의 비정상적인 응집 또는 미스폴딩과 관련된 질환을 예방 또는 치료하기 위한 약학 조성물 |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20040052928A1 (en) | 2002-09-06 | 2004-03-18 | Ehud Gazit | Peptides and methods using same for diagnosing and treating amyloid-associated diseases |
US7781396B2 (en) | 2002-01-31 | 2010-08-24 | Tel Aviv University Future Technology Development L.P. | Peptides directed for diagnosis and treatment of amyloid-associated disease |
US7491699B2 (en) | 2002-12-09 | 2009-02-17 | Ramot At Tel Aviv University Ltd. | Peptide nanostructures and methods of generating and using the same |
EP2058275A1 (de) | 2003-01-07 | 2009-05-13 | Ramot at Tel-Aviv University Ltd. | Peptidnanostrukturen mit einem verkapselten Fremdstoff und Verfahren zu ihrer Herstellung |
KR101215821B1 (ko) | 2003-06-30 | 2012-12-28 | 텔 아비브 유니버시티 퓨쳐 테크놀로지 디벨롭먼트 엘.피. | 아밀로이드 관련 질환을 진단 및 처치하기 위한 펩타이드, 그것에 대한 항체, 및 그 사용방법 |
EP1781310B1 (de) | 2004-08-02 | 2015-10-14 | Ramot at Tel Aviv University Ltd. | Artikel von peptidnanostrukturen und herstellungsverfahren dafür |
EP1973928A2 (de) | 2005-10-11 | 2008-10-01 | Ramot at Tel-Aviv University Ltd. | Selbstzusammengebaute fmoc-ff-hydrogele |
WO2007126111A1 (ja) | 2006-04-28 | 2007-11-08 | Kagoshima University | アミロイドβ線維化阻害ペプチド |
AU2008220785B2 (en) | 2007-03-01 | 2013-02-21 | Vivoryon Therapeutics N.V. | New use of glutaminyl cyclase inhibitors |
US9656991B2 (en) | 2007-04-18 | 2017-05-23 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
PL2475428T3 (pl) | 2009-09-11 | 2015-12-31 | Probiodrug Ag | Pochodne heterocykliczne jako inhibitory cyklazy glutaminowej |
US9181233B2 (en) | 2010-03-03 | 2015-11-10 | Probiodrug Ag | Inhibitors of glutaminyl cyclase |
DK2545047T3 (da) | 2010-03-10 | 2014-07-28 | Probiodrug Ag | Heterocycliske inhibitorer af glutaminylcyclase (QC, EC 2.3.2.5) |
WO2011131748A2 (en) | 2010-04-21 | 2011-10-27 | Probiodrug Ag | Novel inhibitors |
RU2013124827A (ru) * | 2010-10-29 | 2014-12-10 | Мерц Фарма Гмбх Унд Ко. Кгаа | Производные индола и способ их получения |
EP3431489B1 (de) | 2010-11-15 | 2020-12-23 | Ramot at Tel-Aviv University Ltd. | Dipeptidanaloga zur behandlung von störungen im zusammenhang mit amyloid-fibrillen-bildung |
EP2686313B1 (de) | 2011-03-16 | 2016-02-03 | Probiodrug AG | Benzimidazolderivate als glutaminylcyclase-hemmer |
PL2895512T3 (pl) * | 2012-09-12 | 2018-11-30 | Neurimmune Holding Ag | Przeciwciała swoiste dla polipeptydu amyloidowego ludzkich wysepek (HIAPP) i ich zastosowania |
CA3072884A1 (en) * | 2017-08-11 | 2019-02-14 | University Of Kentucky Research Foundation | Anti-neurodegenerative therapeutic, method of manufacture, and use |
PL3461819T3 (pl) | 2017-09-29 | 2020-11-30 | Probiodrug Ag | Inhibitory cyklazy glutaminylowej |
TW202144387A (zh) * | 2020-02-11 | 2021-12-01 | 美商聯合生物醫學公司 | 針對胰島澱粉樣多肽(iapp)的胜肽免疫原及其預防和治療與聚集iapp相關疾病的製劑 |
WO2024121156A1 (en) * | 2022-12-05 | 2024-06-13 | Neurimmune Ag | Cyclic compounds and their use in assays for detecting antibodies |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6344895A (ja) * | 1986-08-13 | 1988-02-25 | Kyowa Hakko Kogyo Co Ltd | 抗アミロイドa蛋白質単クロ−ン性抗体 |
AU7261994A (en) * | 1993-07-19 | 1995-02-20 | Resolution Pharmaceuticals Inc. | Hydrazino-type radionuclide chelators having an n3s configuration |
US6303567B1 (en) * | 1995-03-14 | 2001-10-16 | Praecis Pharmaceuticals, Inc . | Modulators of β-amyloid peptide aggregation comprising D-amino acids |
EP0941334B1 (de) * | 1996-11-06 | 2004-06-02 | THE UNITED STATES OF AMERICA, as represented by the Secretary of the Department of Health and Human Services | Protease-aktivierbare pseudomonas exotoxin-a-ähnliche proproteine |
JP2000193661A (ja) * | 1998-12-25 | 2000-07-14 | Tokyo Rika Kikai Kk | 痴呆症の検査方法 |
-
2003
- 2003-01-30 CA CA2473987A patent/CA2473987C/en not_active Expired - Fee Related
- 2003-01-30 KR KR10-2004-7011868A patent/KR20040081165A/ko not_active Application Discontinuation
- 2003-01-30 JP JP2003563456A patent/JP2006506942A/ja active Pending
- 2003-01-30 EP EP03704977A patent/EP1534310A4/de not_active Withdrawn
- 2003-01-30 WO PCT/IL2003/000079 patent/WO2003063760A2/en active Search and Examination
- 2003-01-30 AU AU2003207973A patent/AU2003207973A1/en not_active Abandoned
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20180061982A (ko) * | 2016-11-30 | 2018-06-08 | 연세대학교 산학협력단 | 세포 내부 pH 감응성 융합 펩티드 및 이를 유효성분으로 포함하는 단백질의 비정상적인 응집 또는 미스폴딩과 관련된 질환을 예방 또는 치료하기 위한 약학 조성물 |
Also Published As
Publication number | Publication date |
---|---|
JP2006506942A (ja) | 2006-03-02 |
EP1534310A4 (de) | 2006-05-31 |
WO2003063760A2 (en) | 2003-08-07 |
EP1534310A2 (de) | 2005-06-01 |
CA2473987C (en) | 2013-11-19 |
WO2003063760A3 (en) | 2005-02-10 |
CA2473987A1 (en) | 2003-08-07 |
AU2003207973A1 (en) | 2003-09-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2719394B1 (de) | Peptide zur Behandlung von amyloidbedingten Erkrankungen | |
US8563273B2 (en) | Method of screening for compounds that disaggregate amyloid aggregates | |
US8012929B2 (en) | Peptides directed for diagnosis and treatment of amyloid-associated diseases | |
KR20040081165A (ko) | 펩타이드 항체 및 이를 이용한 아밀로이드-관련 질환의진단 및 치료 방법 | |
EP1765378B1 (de) | Mittel zur down-regulierung eines msf-a-abhängigen hif-1a und seine verwendung bei der behandlung von krebs | |
US8349801B2 (en) | Peptide ligands for G-protein coupled receptors | |
US20050020809A1 (en) | Peptides antibodies directed thereagainst and methods using same for diagnosing and treating amyloid-associated diseases | |
US20160168212A1 (en) | Compositions for treatment of neurodegenerative diseases | |
AU2004203461B2 (en) | Peptides Antibodies Directed Thereagainst and Methods Using Same for Diagnosing and Treating Amyloid-Associated Diseases | |
IL210418A (en) | Peptides for treating amyloid-associated diseases | |
IL172788A (en) | Use of peptides in the manufacture of medicaments for treating amyloid-associated diseases |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A201 | Request for examination | ||
E902 | Notification of reason for refusal | ||
E90F | Notification of reason for final refusal | ||
E601 | Decision to refuse application |